Announcements Trials
Browse Landscape

Phase

Phase 1 3Phase 2 2Phase 4 1Phase 3 1Phase 1/2 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other neoplasm 1NET 1Gastrointestinal 1Endocrine 1

Conditions

Digestive System Neuroendocrine Tumor G1 1

Interventions

Oxaliplatin 21Capecitabine 19Fluorouracil 16Bevacizumab 16Esomeprazole 11Sorafenib 10Irinotecan 9Leucovorin 8Radiofrequency Ablation 7Propofol 7Bismuth 7Morphine 6Gemcitabine 6Folfox protocol 6Amoxicillin 6lenvatinib 5gadolinium ethoxybenzyl DTPA 5Tetracycline 5Sevoflurane 5S 1 (combination) 5Drug Therapy 5Control Groups 5Cisplatin 5sodium glycididazole 4fish oil triglycerides 4ferric carboxymaltose 4Sodium Chloride 4Ropivacaine 4Ribavirin 4Hepatectomy 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 4 × lutetium Lu 177 dotatate × Gastrointestinal × Clear all
NCT06016855 2025-12-17

Surgical Debulking Prior to Peptide Receptor Radionuclide Therapy in Well Differentiated Gastroenteropancreatic Neuroendocrine Tumors

Vanderbilt-Ingram Cancer Center

Phase 4 Recruiting
6 enrolled
EndocrineGastrointestinalNETOther neoplasm

Digestive System Neuroendocrine Tumor G1

Data powered by HemOnc (CC BY 4.0) Colophon âš¡